Bio-Rad Introduces Anti-Vedolizumab Antibodies
Bio-Rad Anti-Vedolizumab Antibodies
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, announced the release of a range of anti-vedolizumab antibodies.
Vedolizumab (Entyvio) is a monoclonal antibody that is used to treat ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Bio-Rad’s anti-vedolizumab antibodies, which support research into the treatment of these diseases, include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanized IgG1 kappa antibody drug, vedolizumab, and are suitable for development of bioanalytical and patient monitoring assays.
Bio-Rad’s recombinant monoclonal anti-vedolizumab antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display, resulting in highly targeted reagents. The paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. The recombinant production method ensures a consistent and secure supply.
“We are pleased to introduce the anti-vedolizumab antibodies, an exciting addition to Bio-Rad’s industry-leading portfolio of anti-biotherapeutic antibodies,” said Amanda Turner, Product Manager, Custom Antibody Products at Bio-Rad. “We are now able to offer a reliable source of antibodies for the development of bioanalytical assays for vedolizumab, to support research into the treatment of ulcerative colitis and Crohn’s disease.”
Bio-Rad’s anti-vedolizumab antibodies are approved for in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development and patient monitoring.
Vedolizumab (Entyvio) is a monoclonal antibody that is used to treat ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Bio-Rad’s anti-vedolizumab antibodies, which support research into the treatment of these diseases, include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanized IgG1 kappa antibody drug, vedolizumab, and are suitable for development of bioanalytical and patient monitoring assays.
Bio-Rad’s recombinant monoclonal anti-vedolizumab antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display, resulting in highly targeted reagents. The paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. The recombinant production method ensures a consistent and secure supply.
“We are pleased to introduce the anti-vedolizumab antibodies, an exciting addition to Bio-Rad’s industry-leading portfolio of anti-biotherapeutic antibodies,” said Amanda Turner, Product Manager, Custom Antibody Products at Bio-Rad. “We are now able to offer a reliable source of antibodies for the development of bioanalytical assays for vedolizumab, to support research into the treatment of ulcerative colitis and Crohn’s disease.”
Bio-Rad’s anti-vedolizumab antibodies are approved for in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development and patient monitoring.
